Frazier Healthcare Partners raises $419 mln for early-stage life science deals
Frazier Healthcare Partners announced the close of an oversubscribed Frazier Life Sciences IX, its second dedicated life sciences fund, with nearly $419 million in commitments. Led by Managing General Partners Patrick Heron and Jamie Topper, the Frazier life sciences team invests primarily in therapeutics-focused companies developing biopharmaceuticals, with two-thirds of the fund fueling seed and Series A rounds. Exits from 2017 include AnaptysBio (IPO) and Alpine Immune Sciences (reverse merger).
1 November 2017•1 min read
